descriptive
Analysis v1
Strong Opposition
People with obesity or type 2 diabetes who take a drug called retatrutide are more likely to get stomach issues like nausea, throwing up, or constipation—especially if they take higher doses (8 or 12 mg per week). But most people don’t have to stop taking it because of serious side effects.
0
57
Evidence from Studies
Supporting (0)
0
Community contributions welcome
No supporting evidence found
Contradicting (1)
57
Community contributions welcome
57
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Systematic Review With Meta-Analysis
Human
2025The study looked at the same drug and patients as the claim, but found no significant increase in side effects with retatrutide compared to a placebo, which goes against the idea that it causes more stomach problems.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.